Buscar
Mostrando ítems 1-6 de 6
Clinical landscape of LAG-3-targeted therapy
(Elsevier, 2022)
Artículo / Artikulua,
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation ...
Understanding LAG-3 Signaling
(MDPI, 2021)
info:eu-repo/semantics/article,
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
(Springer Nature, 2021)
info:eu-repo/semantics/article,
Background: improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity ...
PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy
(MDPI, 2020)
info:eu-repo/semantics/article,
The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients ...
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
(MDPI, 2020)
info:eu-repo/semantics/article,
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use ...
Cutting-edge CAR engineering: beyond T cells
(MDPI, 2022)
Artículo / Artikulua,
Chimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks ...